Palmidrol is under clinical development by FSD Pharma and currently in Phase I for Fibromyalgia (Fibromyalgia Syndrome). According to GlobalData, Phase I drugs for Fibromyalgia (Fibromyalgia Syndrome) have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Palmidrol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Palmidrol (FSD-201) is under development for the treatment of fibromyalgia.
Ultra-micronized palmitoylethanolamide (UM-PEA) was under development for the treatment of musculoskeletal nociplastic pain associated with idiopathic mast cell activation syndrome (disorder). The drug candidate acts by targeting cannabinoid receptor I and cannabinoid receptor II. The drug candidate is an ultra-micronized palmitoylethanolamide (fatty base) which exerts the desired therapeutic effect at lower doses. It is administered through oral route.
It was under development for cytokine storm associated with acute lung injury in hospitalized COVID-19 patients.
FSD Pharma overview
FSD Pharma is a biotechnology company that develops novel solutions
For a complete picture of Palmidrol’s drug-specific PTSR and LoA scores, buy the report here.